Apadamtase alfa · Adzynma

Protein / enzyme therapeutic

Also known as TAK-755

Approvedregulatory verdict

Evidence outlook

Approved: prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric... (FDA)

This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also approved (1)
US
  • ADZYNMA is indicated for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP)
Product first approved 2023Outside this platform's coverageFDA label

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT04683003 · Takeda
2021-04-14 – 2027-03-16 · Thrombotic Thrombocytopenic Purpura (TTP)
What this study did
NCT03393975 · Baxalta now part of Shire
2017-10-13 – 2024-05-30 · Thrombotic Thrombocytopenic Purpura (TTP)
What this study did
Phase 2 (2)
Acute Ischemic Stroke
NCT07392450 · Takeda
2026-05-17 – 2027-12-06 · Acute Ischemic Stroke
What this study did
Other / comorbidity
NCT05714969 · Takeda
2023-07-21 – 2026-04-16 · Thrombotic Thrombocytopenic Purpura (TTP)
What this study did
Phase 1 (1)
Other / comorbidity
NCT03997760 · Shire
2019-10-21 – 2022-10-26 · Sickle Cell Disease
What this study did

Competitive landscape

This drug's own stage for Acute Ischemic Stroke: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Apadamtase Alfa (Adzynma): this drugPhase 2Protein / enzyme therapeuticADAMTS13not yet gradedNo reviewed efficacy summary in this indication
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorReliable signal
NCT03354429: Composite of Subsequent Stroke or Death (From randomisation (day 1) to visit 3 (day 30-34)): TICAGRELOR 303 Participants | PLACEBO 362 Participants
Edaravone (TTYP01)Phase 3Small moleculeoxidative stressnot yet gradedNo reviewed efficacy summary in this indication
Rinvecalinase AlfaPhase 2/3Protein / enzyme therapeuticTissue kallikrein-1 (KLK1)not yet gradedNo reviewed efficacy summary in this indication
HRS-4029Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
HRS-7450Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
HRS-8829
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Adzynma (Apadamtase alfa) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Phase 3Thrombotic Thrombocytopenic Purpura (TTP)Active not recruiting
Est. primary completion 2027-03-16 · NCT04683003 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Acute Ischemic StrokeRecruiting
Est. primary completion 2027-12-06 · NCT07392450 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

September 2026ApprovalFDA adds Boxed Warning for neutralizing antibodies to ADAMTS13 to ADZYNMA label
US, FDA · FDA · Source ↗